Regeneron Pharmaceuticals

Current directors and officers who also hold a role at another S&P 500 company.

• Christine A. PoonPRU · Director
• Craig B. ThompsonCRL · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Sep 30, 2026

   1.     New Equity Awards for CEO and CSO Effective September 24, 2026 (the “ Grant Date ”), the Compensation Committee (the “ Compensation Committee ”) of the Board of Directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) granted, upon the approval of the independent, non-employee members of the Board, a one-time award of performance share units (together, the “ 2026 PSUs ”) under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the “ Equity Plan ”) to each of Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of the Company (“ CEO ”), and George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of the Company (“ CSO ”), as described below.

   Read the 8-K filing
2. Jan 31, 2024

   On January 26, 2024, based on a previously disclosed Chief Financial Officer succession plan, Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) appointed Christopher Fenimore, currently the Company’s Senior Vice President, Controller, as Senior Vice President, Finance and Chief Financial Officer to succeed the current Chief Financial Officer, Robert E. Landry, who is retiring. On the same day, the Company also appointed Jason Pitofsky, currently the Company’s Vice President, Accounting and Financial Reporting, as Vice President, Controller. Each such appointment will be effective as of the day after Regeneron files its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (expected to occur on February 5, 2024). Mr. Fenimore, 53, has served as Senior Vice President, Controller since January 2021.

   Read the 8-K filing
3. Sep 8, 2023

   Departure of Director On September 1, 2023, Marc Tessier-Lavigne, Ph.D. notified Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) of his decision to retire, effective as of that date, as a director of the Company. Dr. Tessier-Lavigne informed Regeneron that his decision to retire was due to potential conflicts that may arise as he becomes more involved with other companies and was not caused in whole or in part by a disagreement with Regeneron on any matter relating to Regeneron’s operations, policies, or practices. Departure of Chief Financial Officer On September 8, 2023, Robert E. Landry notified the Company of his intention to retire from his position as Executive Vice President, Finance and Chief Financial Officer of the Company in February 2024. Mr. Landry has served as Regeneron’s principal financial officer since 2013.

   Read the 8-K filing
4. Apr 17, 2023

   On April 14 , 2023, P. Roy Vagelos, M.D., Chair of the board of directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”), notified Regeneron of his decision not to stand for re-election at the 2023 Annual Meeting of Shareholders to be held on June 9, 2023 (the “ 2023 Annual Meeting ”). Dr. Vagelos will continue to serve as Chair of the Board for the remainder of his term until the conclusion of the 2023 Annual Meeting. Effective upon the expiration of Dr. Vagelos’s term, the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board (in addition to Dr. Schleifer’s and Dr.

   Read the 8-K filing
5. Oct 3, 2022

   On October 3, 2022, the board of directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (the “ Company ”) elected Craig B. Thompson, M.D. as a director. With the addition of Dr. Thompson, the Board has been expanded from 12 to 13 members. Dr. Thompson has also been appointed to serve on the Technology Committee of the Board. In accordance with the requirements of the New York Business Corporation Law, Dr. Thompson will hold office until the 2023 Annual Shareholder Meeting of the Company. Dr. Thompson will receive compensation from the Company for his service as a director in accordance with the Company’s compensation practices for non-employee directors, as described under the caption “Compensation of Directors” in the Company’s definitive proxy statement filed on April 21, 2022. There is no arrangement or understanding between Dr.

   Read the 8-K filing
6. Jan 5, 2021

   Effective December 31, 2020 (the “ Grant Date ”), the Compensation Committee (the “ Compensation Committee ”) of the Board of Directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) granted, and the non-employee members of the Board approved, in lieu of the next five years of equity awards, a special five-year front-load performance-based equity award under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the “ Equity Plan ”) to each of Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company (“ CEO ”), and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company (“ CSO ”). In revising the compensation structure, the Board took into account shareholder preference for this type of performance-based award.

   Read the 8-K filing
7. Jun 16, 2020

   As described in Item 5.07 below, at the 2020 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) held on June 12, 2020 (the “ Annual Meeting ”), the Company’s shareholders approved the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the “ Plan ”). The Plan was previously adopted by Regeneron’s Board of Directors (the “ Board ”) on April 3, 2020 based upon the recommendation of the Compensation Committee of the Board. A description of the material terms of the Plan is set forth on pages 99 – 106 of the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 24, 2020 (the “ Proxy Statement ”) and is incorporated herein by reference.

   Read the 8-K filing
8. Jan 18, 2018

   On January 15, 2018, Charles A. Baker notified Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) of his intention not to stand for re-election as a member of the board of directors of the Company (the “ Board ”) when his current term expires and to retire from his position as a member of the Board effective as of the conclusion of the 2018 annual meeting of shareholders of the Company (expected to be held on June 8, 2018) . Mr. Baker, 85, joined the Board as its second non-employee member and is retiring after 29 years of service. Mr. Baker’s decision not to stand for re-election was not due to any disagreement with the Company on any matter relating to Regeneron’s operations, policies or practices. 2

   Read the 8-K filing
9. Jan 2, 2018

   Effective January 5, 2018, Robert J. Terifay has resigned as Executive Vice President, Commercial of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) and related positions. Mr. Terifay has been placed on a personal leave of absence as he requested for medical reasons through July 31, 2018. During his leave of absence, he will be able to participate in the Company’s health insurance plans and other similar plans, but will not receive any cash compensation. After the conclusion of his leave of absence on July 31, 2018, Mr. Terifay will retire. Thereafter, Mr. Terifay will be eligible for his continued participation in Regeneron’s health insurance plans subsidized by Regeneron through January 31, 2020. The Company is conducting a search for Mr. Terifay’s replacement.

   Read the 8-K filing
10. Jun 14, 2017

    As described in Item 5.07 below, at the 2017 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) held on June 9, 2017 (the “ Annual Meeting ”), the Company’s shareholders approved the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the “ Plan ”). The Plan was previously adopted by Regeneron’s Board of Directors (the “ Board ”) on April 6, 2017 based upon the recommendation of the Compensation Committee of the Board. A description of the material terms of the Plan is set forth on pages 84 — 91 of the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 25, 2017 (the “ Proxy Statement ”) and is incorporated herein by reference.

    Read the 8-K filing
11. Jan 31, 2017

    (b), (c) Effective March 2, 2017, Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) appointed Christopher Fenimore as Vice President, Controller. As previously reported, the Company’s current controller, Douglas S. McCorkle, is retiring; Mr. McCorkle’s retirement will be effective February 10, 2017. From the effective date of Mr. McCorkle’s retirement until the effective date of Mr. Fenimore’s appointment, the function of the Company’s principal accounting officer will be assumed by Robert E. Landry, Senior Vice President, Finance and Chief Financial Officer. Mr. Fenimore will become the Company’s principal accounting officer on the effective date of his appointment. Mr. Fenimore, 46, has served as Vice President, Deputy Controller since January 2017 and previously served as Vice President, Financial Planning from December 2003 to December 2016.

    Read the 8-K filing
12. Dec 21, 2016

    On December 16, 2016, the Board of Directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) changed the title of George D. Yancopoulos, M.D., Ph.D. from President of Regeneron Laboratories and Chief Scientific Officer of Regeneron to President and Chief Scientific Officer of Regeneron. This change, which was effective immediately, was meant to better align Dr. Yancopoulos’s title with the scope of his current responsibilities at the Company. Leonard S. Schleifer, M.D., Ph.D. continues to serve as President and Chief Executive Officer of the Company.

    Read the 8-K filing
13. Sep 14, 2016

    On September 9, 2016, the board of directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (the “ Company ”) elected Bonnie L. Bassler, Ph.D. as a Class I director and Huda Y. Zoghbi, M.D. as a Class II director to fill the two existing vacancies on the Board. Drs. Bassler and Zoghbi have also been appointed to serve on the Corporate Governance and Compliance Committee and the Technology Committee of the Board. In accordance with the requirements of the New York Business Corporation Law, Drs. Bassler and Zoghbi will hold office until the 2017 Annual Shareholder Meeting of the Company, which is expected to be held on June 9, 2017. Each of Drs.

    Read the 8-K filing
14. Feb 19, 2016

    Director or officer change (Item 5.02). Open the filing for details.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.